Medical sites valuable but inconsistent

Share this article:
Medical Web sites overall have been inconsistent in terms of Web development and low on innovation, according to the Web Marketing Association's (WMA) Internet Standards Assessment Report (ISAR).
The ISAR provides industry benchmarks for Web site development and is based on data from nearly 10,000 Web site evaluations in 80 industries.

Despite lagging behind when compared with other industries, medical Web sites are often easy to use and contain strong copy, according to the report.

“Pharmaceutical Web sites are increasingly reaching out directly to patients as well as the medical community,” the report stated. “These sites have become valuable tools as consumers seek to learn more about medical options and treatments before agreeing to them.”

William Rice, WMA president, explained: “Medical Web sites, and the search capabilities many offer, have helped make patients better consumers by demystifying medicine and making it less overwhelming. Of course … there are others that just don't make the grade.”

The all-volunteer WMA presides over its annual WebAwards competition, which recognizes innovation and excellence in online advertising.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?